Crispr Therapeutics AG (NASDAQ:CRSP)’s stock price traded down 6.3% during trading on Monday . The stock traded as low as $60.88 and last traded at $61.84, 1,473,420 shares traded hands during trading. An increase of 104% from the average session volume of 720,811 shares. The stock had previously closed at $66.01.

Several equities research analysts have recently commented on the company. Goldman Sachs Group boosted their price target on Crispr Therapeutics from $52.00 to $75.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 19th. Zacks Investment Research lowered Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 30th. Roth Capital boosted their price target on Crispr Therapeutics from $65.00 to $100.00 in a research note on Tuesday, November 19th. Canaccord Genuity boosted their price target on Crispr Therapeutics from $72.00 to $80.00 and gave the stock a “positive” rating in a research note on Wednesday, November 20th. Finally, Chardan Capital reissued a “buy” rating and set a $72.50 price target on shares of Crispr Therapeutics in a research note on Monday, November 18th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and twelve have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $71.38.

The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32. The stock has a market capitalization of $3.41 billion, a price-to-earnings ratio of -17.70 and a beta of 3.31. The company has a 50-day moving average of $65.68 and a 200-day moving average of $50.89.

Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The firm had revenue of $211.93 million during the quarter, compared to the consensus estimate of $6.32 million. As a group, analysts expect that Crispr Therapeutics AG will post 0.65 earnings per share for the current year.

In related news, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the transaction, the president now directly owns 33,618 shares in the company, valued at approximately $2,353,260. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total value of $412,500.00. Following the transaction, the director now owns 7,500 shares of the company’s stock, valued at $412,500. The disclosure for this sale can be found here. Insiders have sold a total of 56,118 shares of company stock valued at $3,620,760 over the last 90 days. Insiders own 21.40% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the business. BSW Wealth Partners acquired a new position in Crispr Therapeutics in the 2nd quarter valued at $39,000. Balyasny Asset Management LLC acquired a new position in Crispr Therapeutics in the 2nd quarter valued at $5,165,000. BNP Paribas Arbitrage SA acquired a new position in Crispr Therapeutics in the 2nd quarter valued at $41,000. Bank of New York Mellon Corp raised its holdings in Crispr Therapeutics by 116.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 33,091 shares of the company’s stock valued at $1,559,000 after acquiring an additional 17,810 shares during the last quarter. Finally, First Trust Advisors LP acquired a new position in Crispr Therapeutics in the 3rd quarter valued at $987,000. Institutional investors own 49.82% of the company’s stock.

Crispr Therapeutics Company Profile (NASDAQ:CRSP)

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Recommended Story: Learning About the VIX – Volatility Index



Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.




Source link